secwatch / observer
8-K filed May 25, 2023, 7:59 PM ET ticker INDP CIK 0001857044
other material confidence high sentiment neutral materiality 0.15

Indaptus Therapeutics announces 2023 annual meeting voting results; directors elected, auditor ratified

Indaptus Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Indaptus Therapeutics, Inc. shareholders approved Ratification of the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-05-25
Exact text from the filing
Proposal 2. Ratification of the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Indaptus Therapeutics, Inc. shareholders approved Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal. at the 2023-05-25 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-05-25
Exact text from the filing
Proposal 1 . Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified or until each such director's earlier death, resignation or removal.
View on SEC.gov

Browse all shareholder votes →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-019073
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.